[Active immunotherapy in the treatment of haematological neoplasias].
The continuous search for therapeutic approaches that improve the conventional treatments of neoplasms, together with an improved understanding of the immune system, has led in recent years to the development of Immunotherapy. Basically, a distinction can be made between two forms of immunotherapy: passive immunotherapy, which consists in the transfer of antibodies or cells previously generated in vitro that are directed against the tumour, and active immunotherapy, which attempts to activate in vivo the immune system and induce it to elaborate a specific response against the tumor antibodies. Hematological neoplasms, specifically some B lymphomas, express in their membrane an immunoglobulin that is considered a specific antigen of the tumour, which is why these diseases have become the ideal target for immunotherapy treatments. There are many alternatives, ranging from protein vaccines, which have already shown clinical benefits, to those of the second generation, which make use of the new techniques of molecular biology to increase the efficacy of the vaccines and obtain their production in a quicker and less costly way, but with which there are not yet definitive clinical results.
Inogés
S
S
Area de Terapia Celular, Clínica Universitaria de Navarra. sinoges@unav.es
Rodríguez Calvillo
M
M
López Díaz de Cerio
A
A
Zabalegui
N
N
Melero
I
I
Sánchez Ibarrola
A
A
Rocha
E
E
Bendandi
M
M
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D016233:Immunotherapy, Active / Q000379:methods*; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000276:immunology
D019496:Cancer Vaccines